MRK vs DGX
By Alex · Tickerpine
Merck & Co., Inc. vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DGX |
|---|---|---|
| Price | $128.66 | $209.88 |
| Market cap | $317.77B | $23.23B |
| P/E ratio | 36.2 | 23.2 |
| ROE | 18.94% | 14.54% |
| Profit margin | 13.59% | 9.08% |
| Revenue growth | 4.90% | 9.20% |
| Dividend yield | 2.64% | 1.64% |
| Beta | 0.22 | 0.59 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DGX in plain English
- MRK is the bigger company — about 13.7× the market cap of DGX.
- DGX is cheaper on earnings (P/E 23.2 vs 36.2).
- MRK earns a higher return on equity (19% vs 15%).
- DGX is growing revenue faster (9% vs 5%).
- MRK has the higher dividend yield (2.64% vs 1.64%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.